(NASDAQ: CLDX) Celldex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.86%.
Celldex Therapeutics's earnings in 2026 is -$283,646,000.On average, 15 Wall Street analysts forecast CLDX's earnings for 2026 to be -$347,821,919, with the lowest CLDX earnings forecast at -$366,149,817, and the highest CLDX earnings forecast at -$303,293,366. On average, 15 Wall Street analysts forecast CLDX's earnings for 2027 to be -$353,685,276, with the lowest CLDX earnings forecast at -$419,995,379, and the highest CLDX earnings forecast at -$304,941,700.
In 2028, CLDX is forecast to generate -$246,590,693 in earnings, with the lowest earnings forecast at -$377,688,152 and the highest earnings forecast at -$107,965,845.